Bavdegalutamide

Bavdegalutamide
Clinical data
Other namesARV-110
Identifiers
  • N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC41H43ClFN9O6
Molar mass812.30 g·mol−1
3D model (JSmol)
  • C1CC(CCC1NC(=O)C2=NN=C(C=C2)N3CCC(CC3)CN4CCN(CC4)C5=C(C=C6C(=C5)C(=O)N(C6=O)C7CCC(=O)NC7=O)F)OC8=CC(=C(C=C8)C#N)Cl
  • InChI=InChI=1S/C41H43ClFN9O6/c42-31-19-28(4-1-25(31)22-44)58-27-5-2-26(3-6-27)45-38(54)33-7-9-36(48-47-33)51-13-11-24(12-14-51)23-49-15-17-50(18-16-49)35-21-30-29(20-32(35)43)40(56)52(41(30)57)34-8-10-37(53)46-39(34)55/h1,4,7,9,19-21,24,26-27,34H,2-3,5-6,8,10-18,23H2,(H,45,54)(H,46,53,55)
  • Key:CLCTZVRHDOAUGJ-UHFFFAOYSA-N

Bavdegalutamide is an experimental proteolysis targeting chimera that functions as a androgen receptor degrader.[1] It is being developed to treat metastatic castration-resistant prostate cancer.[2][3][4]

  1. ^ "Bavdegalutamide". PubChem. U.S. National Library of Medicine. Retrieved 2024-10-31.
  2. ^ Shore ND, Shen J, Devitt ME, Lu H, Alicea J, Parameswaran J, et al. (June 2022). "Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer". Journal of Clinical Oncology. 40 (16_suppl): TPS5106. doi:10.1200/JCO.2022.40.16_suppl.TPS5106. ISSN 0732-183X.
  3. ^ "Bavdegalutamide - Arvinas". AdisInsight. Springer Nature Switzerland AG.
  4. ^ Jia X, Han X (February 2023). "Targeting androgen receptor degradation with PROTACs from bench to bedside". Biomedicine & Pharmacotherapy. 158: 114112. doi:10.1016/j.biopha.2022.114112. PMID 36508999.